Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28659888 | 0.79 | NPSR1 (0.58) | SMN1; SMN2LMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL4743968 | 0.79 | NPSR1 (0.64) | SMN1; SMN2LMNAMAPK1POLBRAB9A | |
| SCHEMBL24052074 | 0.72 | LMNA (0.55) | SMN1; SMN2LMNAMAPK1POLBNAMPT | |
| SCHEMBL4743946 | 0.72 | FDPS (0.61) | SMN1; SMN2LMNAMAPK1POLBNAMPT | |
| SCHEMBL28662493 | 0.70 | MEN1 (0.55) | LMNARAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL28660618 | 0.70 | LMNA (0.66) | SMN1; SMN2LMNAMAPK1POLBRAB9A | |
| SCHEMBL28665425 | 0.68 | HTT (0.50) | SMN1; SMN2LMNAMAPK1RAB9ANPC1 | |
| SCHEMBL349933 | 0.68 | NAMPT (0.80) | SMN1; SMN2LMNANAMPTRAB9ANPC1 | |
| SCHEMBL29457342 | 0.68 | NAMPT (0.80) | SMN1; SMN2LMNANAMPTRAB9ANPC1 | |
| SCHEMBL2733293 | 0.67 | RAB9A (0.47) | SMN1; SMN2LMNAPOLBNAMPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SMN1; SMN2 285/4885LMNA 716/4885MAPK1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.